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Abstract
Burning mouth syndrome (BMS) is a chronic pain disorder characterized by severe burning sensation in normal looking oral
mucosa. Diagnosis of BMS remains to be a challenge to oral healthcare professionals because the method for definite
diagnosis is still uncertain. In this study, a quantitative saliva proteomic analysis was performed in order to identify target
proteins in BMS patients’ saliva that may be used as biomarkers for simple, non-invasive detection of the disease. By using
isobaric tags for relative and absolute quantitation labeling and liquid chromatography-tandem mass spectrometry to quantify
1130 saliva proteins between BMS patients and healthy control subjects, we found that 50 proteins were significantly changed
in the BMS patients when compared to the healthy control subjects (p4 0.05, 39 up-regulated and 11 down-regulated). Four
candidates, alpha-enolase, interleukin-18 (IL-18), kallikrein-13 (KLK13), and cathepsin G, were selected for further validation.
Based on enzyme-linked immunosorbent assay measurements, three potential biomarkers, alpha-enolase, IL-18, and KLK13,
were successfully validated. The fold changes for alpha-enolase, IL-18, and KLK13 were determined as 3.6, 2.9, and 2.2
(burning mouth syndrome vs. control), and corresponding receiver operating characteristic values were determined as
0.78, 0.83, and 0.68, respectively. Our findings indicate that testing of the identified protein biomarkers in saliva might be
a valuable clinical tool for BMS detection. Further validation studies of the identified biomarkers or additional candidate
biomarkers are needed to achieve a multi-marker prediction model for improved detection of BMS with high sensitivity
and specificity.
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Introduction
Burning mouth syndrome (BMS) is a chronic pain dis-
order characterized by severe burning sensation in
normal looking oral mucosa. The International
Association for the Study of Pain defines BMS as
‘‘chronic oral mucosal pain or discomfort that has no
identifiable causative lesions and is not caused by any
other condition or disease.’’ The overall prevalence of
BMS in the general population is roughly 4%.1
However, women are three to seven times more likely
than men of a similar age to experience BMS symp-
toms,1,2 especially after the menopause, when its preva-
lence may be 18% to 33%.3 BMS is rarely observed in
patients younger than 30 years of age and prevalence
may increase from 3- to 12-fold with increasing age.1
The disease often affects the tongue (particularly the
tip and lateral borders), lips, and palate. In addition to
a burning sensation, the patients may present unremit-
ting oral mucosal pain, dysgeusia, and xerostomia.2
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BMS was initially considered as a psychogenic illness.
However, over the years, researchers have discovered
objectively measured abnormalities in physiologic
responses of the trigeminal nerves and histopathologic
changes in nociceptive fibers of BMS patients,4–6 suggest-
ing that BMS might be a neuropathic pain disorder.
In fact, studies focusing on trigeminal nerve alter-
ations have shown both hypersensitivity and hyposensi-
tivity as well as large- and small-fiber neuropathy, which
indicate that BMS may have multiple etiologies produ-
cing similar symptoms.5–8 Recently, investigators
have examined BMS patients for central neural changes,
specifically on dopamine receptors in the basal ganglia,
and found that BMS is associated with a decline
in endogenous dopamine levels in the putamen, which
results in altered central nociceptive signal processing.9,10
These findings suggest that brain function alters along
with peripheral nerve changes and support the
notion that central modulation of sensory signal occurs
in BMS patients. Nevertheless, the etiology and patho-
physiology of BMS are not well understood, and
the exact cause of neuropathy in BMS remains
unknown. Consequently, there has been no effective
treatment for the patients with BMS. A thorough under-
standing of the pathogenesis and etiology of this disease,
combined with novel diagnostics and therapeutic inter-
ventions, is required for an improved management of
BMS patients.
Quantitative proteomics is a powerful methodology
for biomedical applications because it allows global pro-
filing of proteomic samples from disease patients to
reveal significantly altered proteins that may serve as tar-
gets for disease diagnosis, prognosis, and/or thera-
peutics.11–13 In order to profile proteins present in the
saliva samples from BMS patients, we used a quantita-
tive proteomics approach based on isobaric tags for rela-
tive and absolute quantitation (iTRAQ) and liquid
chromatography-tandem mass spectrometry (LC-MS/
MS). iTRAQ is a stable isotope labeling method which
allows for concurrent identification and quantification of
proteins from up to eight samples within a same experi-
ment.14 Upon labeling by iTRAQ 8-plex isobaric tags
(reporter ions, m/z 113, 114, 115, 116, 117, 118, 119,
and 121), peptide samples derived from eight protein
samples can be combined and analyzed with a single
LC-MS/MS run. The isobaric tags are cleaved during
higher energy collision dissociation (HCD) to yield an
isotope series (reporter ions) representing the quantity
of a single peptide of known mass from eight different
samples. Since the peptide remains attached to the iso-
baric tags until HCD is conducted, the peptide is simul-
taneously fragmented for sequence identification.
Therefore, the relative intensities of the reporter ions
(ratios) represent the relative abundance of each peptide
among the eight samples, and the relative abundance of
each protein among the eight samples is computed from
the ratios of each unique peptides derived from the
protein.
The purpose of the present study is to identify target
proteins present in BMS patients’ saliva that may be
used as biomarkers for simple, non-invasive detection
of BMS. First, a quantitative proteomics approach
based on LC-MS/MS and iTRAQ was used to relatively
quantify all saliva proteins between BMS and healthy
control groups. Second, statistical analysis was used
to identify proteins at significantly altered levels
between BMS and healthy control groups, and a panel
of candidate biomarkers were further validated with
enzyme-linked immunosorbent assay (ELISA). Lastly,
statistical analysis was performed to evaluate the per-
formance of the validated potential biomarkers for
BMS detection.
Materials and methods
Sample collection
This study was approved by the institutional review
board committee at the University of California Los
Angeles, and all BMS and healthy control subjects
signed the consent form prior to sample collection. In
total, 38 subjects were recruited for this study, including
19 BMS patients and 19 healthy control subjects. Both
BMS patients and healthy control subjects do not have
intraoral inflammation such as gingivitis and periodontal
disease to avoid other putative biomarkers, pro-inflam-
matory mediators, being detected in proteomic profile
data. Originally, there were more than 19 BMS patients;
however, since they were either taking other medication
for other disorders/diseases or had visual analog scale
(VAS) scale less than 3, they were excluded for this pro-
ject to reduce accounting various variables. All BMS
patients were recently diagnosed and had not received
any prior treatment before sample collection, and all
control subjects had never experienced any oral burning.
These all BMS patients claimed having burning sensa-
tion inside of their mouth, dried mouth, and idiopathic
pain inside their mouth. Whole saliva samples were col-
lected using a well-defined and standardized proto-
col.15–18 The whole saliva samples were unstimulated,
and each individual does not have any other inflamma-
tion in his or her mouth. In order to prevent any con-
tamination from other sources, we asked patients to rinse
their mouth thoroughly before collecting saliva. Once
collected, the samples were centrifuged at 10,000 g
for 10min at 4C to separate supernatant from cell pel-
lets and debris. The supernatant was then aliquoted and
stored at 80C. The samples were thawed out only once
for measurement in order to prevent protein degrad-
ation. Total protein concentration of saliva samples
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was measured with the 2-D Quant Kit (GE Healthcare,
Pittsburgh, PA, USA).
Gel electrophoresis
Saliva samples with a total protein amount of 60 mg were
separated with the NUPAGE Novex 4%–12% Bis-Tris
gels (Invitrogen, Carlsbad, CA, USA), and the gels were
fixed for 30min with 50% methanol and 10% acetic acid.
(Note: In order to normalize the total protein amount for
all samples and visualize fine protein bands, we selected
the 60 mg as minimum quantity for each sample.) After
fixation, the gels were stained with the SimplyBlue
SafeStain (Invitrogen) for 40min at room temperature
to visualize the protein bands. Gel lanes were excised
for subsequent in-gel tryptic digestion and iTRAQ label-
ing of the resulting peptides.
Quantitative proteomic analysis
Each lane of protein gel pieces were reduced using tris (2-
carboxyethyl) phosphine (TCEP) and alkylated with
methyl methanethiosulfonate (MMTS) followed by tryp-
sin digestion in 50mM TEAB buffer at 37C for 16 h.
After proteolytic cleavage, the resulting peptides from
each sample were labeled with iTRAQ labeling reagents
(8-plex kit; AB SCIEX, Framingham, MA, USA). The
BMS samples were labeled with iTRAQ reagents 113 to
116 and the control subjects were labeled with iTRAQ
117 to 121. The resulting peptides were combined and
separated by SCX using a polySULFOETHYL A
column (4.6mm 200mm, 5 mm, 300 A˚; Poly LC Inc.,
Columbia, MD, USA). Total 20 fractions were collected.
Each fraction was desalted using the PepClean C18 spin
columns (Pierce, Rockford, IL, USA) and further ana-
lyzed by RPLC-MS/MS on the Orbitrap Velos instru-
ment. The peptide samples were loaded onto a C18 trap
column at a flow rate of 30 ml/min. Then, the peptides
were separated on a C18 nano column (75 mm 150mm,
3 mm, 100 A˚, C18; Dionex, Sunnyvale, CA, USA) at a flow
rate of 250 nl/min on an UltiMate 3000 LC system
(Dionex) using 3 h gradient. The MS/MS spectra were
acquired on the Orbitrap Velos mass spectrometer using
a data-dependent analysis mode, which the top 10 most
abundant ions in each MS scan (m/z 350–2000) were
selected for MS/MS analysis. The capillary temperature
was set to 275C and the spray voltage set to 2 kV. The
resolution for MS scan is 60,000 full width at half max-
imum (FWHM) and 7500 FWHM for MS/MS scan. The
lock mass was used for accurate mass measurement. The
MS/MS spectra were searched against the UniRef100
human database (120,982 entries) using the Mascot
Daemon (Version 2.3). The mass tolerance was 10 ppm
for MS and 0.1 Da for MS/MS. The variable modifica-
tions include methionine oxidation and tyrosine iTRAQ
labeling. The fixed modifications include N-terminus and
Lysine side chain 8-plex iTRAQ labeling and cysteine
MMTS alkylation. All the protein and peptides were
identified with a false discovery rate less than 1%.
The relative quantitation was calculated as the aver-
age fold changes of identified proteins in BMS patients
as compared to the average fold changes of the proteins
in control subjects. The median ratio was used for
normalization.
Enzyme-linked immunosorbent assay
ELISA was used to quantify the levels of four candidate
biomarkers in BMS patients (n¼ 15) and healthy control
subjects (n¼ 15). The following commercially available
ELISA kits were used: alpha-enolase (Abcam Inc., USA,
#ab181417); interleukin-18 ((IL-18)) (R&D Systems Inc.,
USA, #7620); kallikrein-13 (KLK13) (Sino Biological
Inc., China, #SEK10199-5); and cathepsin G (Abnova
Corporation., USA, #KA1265).
Statistical analysis
Statistical analysis of the proteomics data was performed
with simple Student t-test. Statistical analysis of the val-
idation data was performed with the MedCalc statistical
software (MedCalc Software Co., Ostend, Belgium), and
the receiver operating characteristic (ROC) analysis was
used to estimate the performance of each potential
biomarkers.
Results
The purpose of this study is to identify target proteins
present in BMS patients’ saliva that may be used for
non-invasive detection of the disease. The study design
is very straightforward, as shown in Figure 1. First, a
quantitative proteomics approach was used to relatively
quantify global saliva protein levels between BMS
patients and healthy control subjects. Second, statistical
analysis was used to identify differentially expressed pro-
teins between BMS and healthy control subjects. Next, a
panel of candidate biomarkers were chosen for ELISA
validation, and statistical analysis was performed to
evaluate the performance of the potential biomarkers
for BMS detection.
Quantitative proteomic analysis
Since the 8-plex iTRAQ kit allows to label eight protein
samples, we chose four BMS and four control samples
for a two-group comparative proteomic analysis. These
BMS patients and control subjects were well matched in
terms of gender, age, and ethnicity to minimize potential
bias from these factors during the discovery phase. Prior
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to iTRAQ labeling, total protein concentrations of the
eight samples were measured so that equal amount of
proteins (60 mg in total) from each samples was used
for iTRAQ labeling. Afterwards, SDS-PAGE was used
to separate the proteins from the eight samples
(Figure 2(a)), and individual gel lanes were excised for
in-gel tryptic digestion and iTRAQ labeling of the result-
ing peptides.
After 8-plex iTRAQ labeling, the eight labeled peptide
samples (four BMS and four controls) were combined
and analyzed with LC-MS/MS. In total, we quantified
more than 1100 proteins with more than 7500 identified
peptides from each BMS or control samples (Figure 2(c)).
The relative quantitation was computed as the average
fold change of the identified protein in four BMS samples
as compared to the average fold change of the protein
from four control subjects, and the median ratio was
used for normalization. Figure 2(b) illustrates the
iTRAQ reporter ion ratios for 1130 proteins, which
show the relative levels of these proteins between the
BMS and healthy control groups. The complete list of
quantified proteins from all the eight samples (four
Figure 1. The workflow for discovery of potential saliva protein
biomarkers of BMS.
Figure 2. Relative quantitation of salivary proteins between BMS patents (n¼ 4) and healthy control subjects (n¼ 4). Quantitative
proteomic analysis was based on SDS-PAGE separation of saliva proteins, tryptic digestion of gel-separation proteins, iTRAQ labeling of
extracted peptides, and LC-MS/MS analysis of iTRAQ-labeled peptides. (a) SDS-PAGE separation of saliva proteins of BMS and control
subjects. (b) Relative ratios of iTRAQ reporter ions which represent the relative levels of 1130 saliva proteins between BMS and healthy
control subjects. (c) p values for 1130 quantified proteins between BMS and healthy control groups. (d) Average number of proteins
quantified from the BMS or control groups.
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BMS and four healthy controls) is shown in
Supplemental Table 1.
Statistical analysis of the quantitative proteomics data
revealed that 50 proteins were significantly (p4 0.05)
changed in the BMS patients when compared to the
healthy control subjects. Among this group of proteins,
39 ones showed significantly increased levels whereas the
remaining 11 ones showed significantly decreased levels
in BMS patients versus healthy control subjects
(Supplemental Tables 2 and 3).
ELISA for validation
Among the 39 proteins that showed significant increased
levels in BMS patients, we ranked them by fold changes.
Based on the fold change as well as previous studies in
the literature about their function, we selected four can-
didates, KLK13, cathepsin G, alpha-enolase, and IL-18
for further validation.
The validation results for KLK13, cathepsin G,
alpha-enolase, and IL-18 are shown in Figure 3. Based
on ELISA measurement, the levels of alpha-enolase, IL-
18, and KLK13 were found to be significantly elevated in
BMS versus control group (n¼ 15 per group). The fold
changes (BMS vs. control) for alpha-enolase, KLK13,
and IL-18 were determined as 3.6, 2.2, and 2.9, with p
values of 0.002, 0.04, and 0.02, respectively (Table 1).
However, ELISA measurement suggests that cathepsin
G levels were not significantly different between BMS
patients and control subjects. ROC analysis was per-
formed to estimate the performance of these
candidate biomarkers (Figure 4) and the results are
shown in Table 1.
Discussion
BMS is a chronic pain disorder characterized by severe
burning and stinging of the oral cavity in the absence of
any organic disease. It may last at least four months to a
number of years and significantly deteriorates patients’
quality of life. Diagnosis of BMS remains to be a chal-
lenge to oral healthcare professionals due to the discrep-
ancy between the severity, extensive objective pain felt by
the patient, and the presence of limited clinical changes
of the oral mucosa. Despite a number of clinical tests
that have been proposed for BMS patients, the methods
of definite diagnosis for BMS are still uncertain. In add-
ition, the symptoms and clinical tests of BMS are not
Figure 3. ELISA validation of four candidates, IL-18, alpha-enolase, KLK13, and cathepsin G, between BMS and healthy control subjects
(n¼ 15 per group).
Table 1. Performance of the potential biomarkers based on
ELISA validation.
Protein
biomarker
Fold
change p
Sensitivity
(%)
Specificity
(%)
ROC
value
Alpha-enolase 3.6 0.002 66.7 93.3 0.78
Kallikrein-13 2.2 0.04 53.3 80.0 0.68
Interleukin 18 2.9 0.02 93.3 60.0 0.83
Cathepsin G 1.3 0.47 86.7 46.7 0.60
ROC: receiver operating characteristic.
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well-known to general population, which causes signifi-
cant delay in diagnosis of the disease.
Currently, a number of tests/examinations have been
recommended for helping diagnose BMS in oral medi-
cine clinics, such as measuring salivary flow rate, testing
hematology (complete blood count, glucose levels, and
nutritional factors), examining oral cavities, testing pain
intensity using a VAS, culturing fungus from oral
mucosa, and testing allergy from medication or foods
by eliminating one at a time.19–21 Due to various and
unknown causes of BMS, clinicians even perform a
number of different tests to exam BMS patients, so
that they can propose suitable treatment for individual
BMS patient in respect to their clinical histories.
Although there are classification approaches for BMS
patients based on their conditions, background, or symp-
toms, clinicians cannot explicitly tell the patients they
have definite diagnosis of BMS and what causes them
to have BMS during their first clinic visits because there
is no standardized test available yet. BMS may share
similar symptoms to Sjogren’s syndrome which is an
autoimmune disease that causes patients to have clinic-
ally dry mouth and eyes symptoms.16,17,22 A common
practice in oral medicine clinics is that, when BMS
patients claim dry mouth symptoms, clinicians would
refer the patients to test first for Sjo¨gren’s syndrome.
In this regard, a reliable clinical test for BMS would be
very valuable to differentiate BMS from Sjo¨gren’s syn-
drome patients.
One effective way to contribute to finding a clinical
test for BMS is to discover multiple biomarkers that can
be combined to achieve a sensitive and specific detection
of the disease. Saliva is a body fluid that can be easily
and repeatedly collected from patients to help diagnose
and monitor diseases. Therefore, in this study, we aim to
conduct a quantitative proteomic analysis of saliva sam-
ples from BMS patients and healthy control subjects in
order to identify differentially expressed proteins that
may serve as biomarkers for BMS detection.
Our quantitative proteomic analysis based on iTRAQ
labeling and LC-MS/MS indicated that the saliva prote-
omes of BMS patients are distinct from those of healthy
control subjects. The proteomic alterations may result
from the peripheral nerve changes in oral cavity, particu-
larly in the tongue and salivary gland tissues. Meanwhile,
these proteomic changes, particularly the decreased
Figure 4. ROC analysis of the four potential biomarkers based on ELSIA validation data. The performance of these candidate biomarkers
is shown in Table 1.
6 Molecular Pain
expression of important functional saliva proteins, might
contribute to the dysgeusia and xerostomia symptoms
felted by certain BMS patients. Our studies suggested
that there are similarities and dissimilarities between
the saliva proteomes of BMS patients and those of
Sjo¨gren’s syndrome patients. For instance, carbonic
anhydrase 6 and b2-microglobulin were significantly
up-regulated in patients with Sjo¨gren’s syndrome but
barely changed in those with BMS. Prolactin-
inducible protein was down-regulated in Sjo¨gren’s syn-
drome patients but up-regulated in BMS patients.
However, alpha-enolase and carbonic anhydrase 2 were
up-regulated in both BMS and Sjo¨gren’s syndrome
whereas lysozyme C was down-regulated in both BMS
and Sjo¨gren’s syndrome.22
Among the 39 proteins that showed significantly
increased levels in BMS patients, four candidates, IL-
18, alpha-enolase, KLK13, and cathepsin G, were
chosen for further validation. Three potential bio-
markers, IL-18, alpha-enolase, and KLK13, were suc-
cessfully validated with ELISA, which showed
consistently elevated expression levels in BMS patients
as revealed by the proteomic analysis. IL-18 is a pro-
inflammatory cytokine which acts as an inflammatory
mediator in body fluids.23 In fact, IL-18 is considered
as a potential factor in immune response that induces
chronic inflammation in different diseases such as
rheumatoid arthritis, psoriatic arthritis, Crohn’s disease,
and Sjogren’s syndrome.23,24 Human kallikreins are pro-
teolytic enzymes known to be overexpressed in many
types of carcinomas to enhance invasiveness and meta-
static characteristics of tumors.25 They are also
involved in inflammatory response by activating kinins
(polypeptides formed by kallikrein) through cleaving the
high-molecular-weight kininogen.26 These kinins play
important roles in regulating inflammatory process and
pain responses because activated kinins enhance the vas-
cular permeability. A previous study actually predicted
that kallikreins are elevated in BMS patients and
increased activity of kallikrein promotes the inflamma-
tion process in oral mucosa of BMS patients.26 Alpha-
enolase, a glycolytic enzyme, also plays a role in immune
response as a cell surface receptor for plasminogen on
pathogens, such as streptococci, and activated immune
cells, leading to systemic infection or tissue invasion.27
Anti-alpha enolase is often found in different types
of autoimmune and inflammatory diseases and cancers
where alpha-enolase is upregulated compared to healthy
controls.28 Our previous study also demonstrated that
alpha-enolase was at elevated levels in saliva from
Sjo¨gren’s syndrome patients.22
As shown in Figure 3, elevated levels of these proteins
were only observed in a partial group of BMS patients,
and there were overlaps for their expression between
BMS and control group. This might reduce the power
of the analysis if these markers are used in clinic.
Therefore, we need further estimate the performance of
these potential biomarkers with ROC analysis. As shown
in Figure 4, according to the ROC analysis, alpha-eno-
lase and IL-18 appeared to be more valuable biomarkers
than KLK13 and cathepsin G because they showed
higher ROC values and their expression levels were sig-
nificantly higher in BMS patients than the control sub-
jects. In addition, further studies are warranted to
confirm the clinical utility of these potential biomarkers.
IL-18 and KLK13 seem to be unique biomarkers to
BMS as they were not significantly changed in
Sjo¨gren’s syndrome patients.22 However, saliva alpha-
enolase levels were significantly elevated in both BMS
and Sjo¨gren’s syndrome patients. Nevertheless, we need
further test these potential biomarkers in new BMS
patient population and also Sjo¨gren’s syndrome patients.
With additional studies to further validate their clinical
value among larger patient cohorts, we may be able com-
bine these potential biomarkers or with other clinical
indicators to accomplish a significantly improved detec-
tion of BMS.
Conclusion
In summary, our quantitative proteomic analysis indi-
cated that there are significant changes to the saliva
proteomes of BMS patients compared to healthy control
subjects. By using ELISA for validation, we found that
alpha-enolase, IL-18, and KLK13 are potentially valu-
able biomarkers for BMS. Since these proteins are over-
expressed in saliva from BMS patients, they are possibly
associated with peripheral nerve damage or increased
inflammatory response in the oral cavity of the patients.
To the best of our knowledge, this is the first quantitative
proteomics study of BMS. Our findings have shown that
testing of the identified protein biomarkers in saliva
might be a valuable tool for BMS detection. In the
future, a multi-center clinical trial is needed to further
validate the identified biomarkers or additional candi-
date biomarkers so that a multi-marker prediction
model can be achieved for an improved detection of
BMS with high sensitivity and specificity.
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